Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
But with Derm Assist available free, how will the company make money?
Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.
But does it hit hard enough?